MEDICINOVA, INC. Accounts Receivable, Allowance for Credit Loss, Current
MEDICINOVA, INC. (MNOV) had Accounts Receivable, Allowance for Credit Loss, Current of $0 as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent · last filed 2026-08-13
- 2026-06-30: Accounts Receivable, Allowance for Credit Loss, Current $0.00.
- 2026-03-31: Accounts Receivable, Allowance for Credit Loss, Current $0.00.
- 2025-09-30: Accounts Receivable, Allowance for Credit Loss, Current $0.00.
- 2025-06-30: Accounts Receivable, Allowance for Credit Loss, Current $0.00.
| Period end | Accounts Receivable, Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-13 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |